LY4175408 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called LY4175408 (an experimental treatment) for individuals with certain advanced cancers, such as some types of lung, breast, and endometrial cancer. Researchers aim to determine the treatment's safety, effectiveness, and how the body processes it. They are particularly interested in the drug's absorption into the bloodstream and its duration in the body. This trial seeks participants who have exhausted all standard cancer treatments available to them and still need other options. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that LY4175408 is likely to be safe for humans?
Research is ongoing to determine the safety of LY4175408 for people with advanced cancer. As the treatment is in early testing stages, clear safety information is not yet available. Researchers are currently identifying the best dose and monitoring for side effects.
While it is too early to assess tolerance to LY4175408, these early trials aim to establish safe dosage levels and identify any potential negative effects. Participants in these studies receive close monitoring to ensure their safety. It is important to note that treatments in early trials often have limited safety information, as researchers continue to collect data.12345Why do researchers think this study treatment might be promising?
Unlike the standard cancer treatments that often involve chemotherapy or targeted therapies, LY4175408 stands out due to its innovative mechanism of action. Most treatments attack cancer cells directly, whereas LY4175408 is designed to leverage the body's immune system to target and destroy cancer cells more precisely. This approach could potentially result in fewer side effects compared to traditional chemotherapy, which can harm healthy cells. Researchers are excited because LY4175408's unique intravenous administration is being tested for both optimal dosing and effectiveness, aiming to maximize benefits while minimizing risks.
What evidence suggests that LY4175408 might be an effective treatment for cancer?
Research has shown that LY4175408 could be a promising treatment for some advanced cancers. This drug combines an antibody with a cancer-fighting agent, specifically targeting and destroying cancer cells. Early lab and animal studies demonstrated its effectiveness against tumors with the PTK7 protein, common in many cancers. These studies showed positive results, particularly for triple-negative breast cancer, which does not respond to certain hormone treatments. Although human studies remain limited, these initial findings suggest potential effectiveness for advanced cancers with PTK7. Participants in this trial will receive LY4175408 in various dosing regimens to evaluate its safety and effectiveness.13567
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for individuals with advanced stages of various cancers, including lung, endometrial, breast, and pancreatic cancer. Participants should have a specific type of these cancers to join the study. The full eligibility criteria are not provided here.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1a Dose Escalation
Escalating doses of LY4175408 administered intravenously (IV) to determine safety and optimal dosing
Phase 1a Dose Optimization
Two or more doses of LY4175408 (evaluated during dose escalation) administered IV to optimize dosing
Phase 1b Dose Expansion
LY4175408 administered IV to further assess safety and efficacy in a larger cohort
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY4175408
Trial Overview
The trial is testing LY4175408's safety and effectiveness in treating certain advanced cancers. It also studies how this drug behaves in the body regarding absorption, breakdown, and elimination over a period that could last up to four years.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
LY4175408 administered IV
Two or more doses of LY4175408 (evaluated during dose escalation) administered IV
Escalating doses of LY4175408 administered intravenously (IV)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University
Citations
A Study of LY4175408 in Participants With Advanced Cancer
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will ...
A Study of LY4175408 in Participants With Advanced Cancer
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will ...
Anti-lipolysis-stimulated lipoprotein receptor antibody-drug ...
This study used MDA-MB-231 and 4T1 cell lines for in vitro anti-cancer cytotoxicity assays and in vivo anti-TNBC efficacy evaluations.
PTK7 Antibody-Drug Conjugate Molecule - Learn More
It has a drug-antibody ratio (DAR) of 8:1. In preclinical models, LY4175408 has shown activity against a range of PTK7-expressing tumors, including low and ...
Conjugates dominate human trial entries | ApexOnco
The first-in-human study of LY4175408 starts this month, and makes this molecule the sixth anti-PTK7 ADC to enter clinical development. Two of ...
ly4175408 ptk7 antibody-drug conjugate
The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and ...
LY4175408 for Cancer · Recruiting Participants for Phase ...
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.